IL17A and type 2 diabetes mellitus: Notably, GQD predominantly acts on immuno-inflammatory pathways, such as Toll-like receptors, IL-17, TNF, MAPK, and the PI3K-Akt signaling pathways, in the simultaneous treatment of T2DM and UC.